{"entity":{"id":"nct06991556","kind":"trial","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","aka":[],"tldr":"A phase 2 trial of Abiraterone acetate, Enzalutamide in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) is a phase 2 interventional study registered as NCT06991556 by Novartis Pharmaceuticals, with 168 participants enrolled, started 2025-07-07 and due to reach its primary completion in 2032-02-13. Interventions recorded: JSB462, Abiraterone, Enzalutamide. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06991556","url":"https://clinicaltrials.gov/study/NCT06991556"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","enzalutamide"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06991556","phase":"2","setting":"A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","sponsor":"Novartis Pharmaceuticals","enrolled":168,"outcomes":[]},"route":"/trials/nct06991556/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}